The results of the three large European cohort studies have been confirmed in two smaller New Zealand birth cohorts. Arsenault and colleagues (2002) reported a prospective study of the relationship between adolescent cannabis use and psychosis in a New Zealand birth cohort (n = 759). They found a relationship between cannabis use by age 15 and an increased risk of psychotic symptoms by age 26. The relationship did not change when they controlled for other drug use, but it was no longer statistically significant after adjusting for psychotic symptoms at age 11. The latter probably reflected the small number of psychotic disorders observed in the sample. Fergusson et al. (2003) found a relationship between cannabis dependence at age 18 and later symptoms that included those in the psychotic spectrum reported at age 21 in the Christchurch birth cohort. Fergusson and colleagues adjusted for a large number of potential confounding variables, including self-reported psychotic symptoms at the previous assessment, other drug use and other psychiatric disorders, but whether the association represents a link between cannabis use and psychotic symptoms specifically, or more general psychiatric morbidity, remains unclear.
“Twenty-one of those doctors are based in New South Wales, and there are two in Queensland. All of these doctors are paediatric neurologists. They are authorised specifically to prescribe to children with neurological conditions. That means patients with other conditions, for example terminal cancer, cannot access medical cannabis through these authorised prescribers.”
In the United States, we're in the middle of a cannabis revolution. Our nation is slowly waking up to the truth that cannabis, what was once dubiously considered a dangerous psychoactive substance, is not only safe but extremely versatile in its medical benefits. This has been reflected in the sales of legal cannabis products, which is expected to grow from $6.6 billion in 2016 to $24.1 billion in 2025.
There are approximately 60 unique cannabinoids in cannabis plants, which can be classified as hemp plants or marijuana plants (there’s a difference!). CBD is one of them and is the second-most prevalent cannabinoid found in the plant; THC is another. This distinction is absolutely critical to understand because THC is the cannabinoid responsible for the “high” produced by traditional marijuana; it’s where the negative connotations and associations generally begin.
CBD oil alleviates physical pain and anxiety – both of which can have a negative impact on sleep. Additionally, CBD oil can actually prolong sleep for some, leading to more rest from night to night. Most medical experts agree that marijuana is not particularly beneficial for individuals with medical conditions and/or mental health disorders, as the THC can increase their symptoms; this makes CBD oil a good alternative option for people with the following sleep disorders and medical conditions.
14. In making the two previous determinations about THC, why did FDA conclude that THC is an active ingredient in a drug product that has been approved under section 505 of the FD&C Act? In making the two previous determinations about CBD, why did FDA determine that substantial clinical investigations have been authorized for and/or instituted, and that the existence of such investigations has been made public?
When used as treatment for pain, CBD has a powerful effect on neuropathic pain, which is pain of the nerves and might be caused by peripheral nerve injury or other factors. By activating CB2 receptors, CBD activates many of the pathways that ease pain, and this goes a long way towards managing long term conditions such as diabetes, MS, and fibromyalgia.

CBD

×